| Prev Close | 16.50 |
| Open | 16.34 |
| Day Low/High | 16.01 / 16.98 |
| 52 Wk Low/High | 9.60 / 26.81 |
| Volume | 711.04K |
Heron Therapeutics Inc (HRTX)
16.47
0.03
0.18
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 90.86B |
| Market Cap | 1.49B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Just Another Wild Day on the Small-Cap Biotech Rollercoaster
Use long-dated calls to take some of risk out of this inherently high-beta space.
If You Like Laggards, Here Are 3 to Consider
These companies will benefit immensely as the country experiences a burst of economic growth.
These 3 Biotechs Have Decent Values
One would need to use covered calls to initiate positions that provide a solid amount of downside protection.
Markets, FDA, Manhattan Real Estate, New York City Exodus
Some acceleration in losses across the major indices since out last update. With options expiration today, we could see some volatility in the last hour of trading. My covered calls referenced in a previous post have not hit yet but have a good chan...
Bank Stress Tests, FDA Drug Approvals, Covid-19
Pre-market futures are now pointing to a slightly down open. Bank stress test have the financial sector under pressure as the Financial Select Sector SPDR ETF is down over 1% close to the opening bell. Zogenix should have a good day. The FDA approve...
Watch These Biotech Names on Strong Earnings
Merger activity is the number 1 driver I am watching for biotech growth.
Putting My Covered Call Strategy to Work With 2 Dinged Biotech Stocks
Sharp drops in Heron Therapeutics and Supernus Pharmaceuticals have presented opportunities to make lemonade out of lemons.
2 Small Biotech Stocks Spurt Ahead on Positive Developments
Heron Therapeutics and TG Therapeutics each gave investors reasons for cheer in the last few days.
A Good Day for Biotechs
The market has strengthened a bit since our last update. T2 Biosystems is now up over 50% on positive developments that we chronicled in my last post. Lexicon Pharmaceuticals is up some 30% today off oversold levels. It should receive some $260 mil...
China Trade Truce, Biotech Fuel Action
Markets continue to be nicely in the black two hours into trading as resumption of U.S.-China trade talks have investors in a good mood to start off the second half of trading in 2019. Some small biotechs continue to show some strength this Monday. ...
Dealing With Biotech Stocks That Face Setbacks
Knowing when to continue to fish or cut bait is something that develops over time in this space.
These 3 Biotech Stocks Are Moving Closer to Profitability
Here are updates on small biotech/biopharma names I have profiled before.
3 Promising Small Biotech Stocks to Watch
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
Markets Struggle to Find Direction
Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...
Consider These Tier 3 Biotechs
I hope we get a decent size market decline so I can add to some stakes in what I think are already undervalued biotech holdings.
Biotech Shows Strength
The major indices have improved a tad since our last update. Biotech has shown some strength over the past two hours or so. There are two names to keep an eye on: T2 Biosystems has been strong so far in 2018, moving from around $4 to over $5 a shar...
5 Small Biotechs Receive Shots in the Arm
Favorable quarterly results and FDA drug approvals should help lift these five names.
5 Small Biotechs Receive Shots in the Arm
Favorable quarterly results and FDA drug approvals should help lift these five names.
Market Wrap: Stocks Sink Across the Board
Materials and technology names led the way down on the session.
Bearish Charts of the Week: SPY, IWM
The markets have given us lots to think about here.
More Morning Musings
It appears based on the futures that the market's rally will continue today, at least at the open. Personally, I think investors are becoming complacent given what could unfold in Greece over the next week. Everyone seems to be betting that Europe w...
Where the Money Was Made the Last 5 Years
Only one fund category (of 20) has beaten the S&P 500 over half a decade.